A clinical study to assess response of a drug that treats low red blood cells count in chronic kidney disease patients
Not Applicable
- Conditions
- Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)Health Condition 2: N184- Chronic kidney disease, stage 4 (severe)Health Condition 3: N185- Chronic kidney disease, stage 5Health Condition 4: N186- End stage renal disease
- Registration Number
- CTRI/2024/01/060994
- Lead Sponsor
- BHAWNA SAINI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age 18-70 years of either sex
2. Patients that have CKD Stage-3-5
Exclusion Criteria
1. Infectious disease
2. Active liver disease
3. Neoplastic disease on cytotoxic chemotherapy
4. Recent cardio-cerebrovascular disease
5. Blood transfusions or surgical procedures within last 4 weeks
6. Active bleeding or pure red cell aplasia
7. Patients receiving phosphate binder containing magnesium or laxatives containing magnesium.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method •To study the serum magnesium level in CKD stage 3-5 patientsTimepoint: •To study the serum magnesium level in CKD stage 3-5 patients
- Secondary Outcome Measures
Name Time Method To correlate serum magnesium level with the erythropoiesis stimulating agents responsiveness in the anemia in chronic kidney disease patientTimepoint: BASELINE (DAY-1) AND AFTER 1 MONTH;To correlate serum magnesium level with the severity of anemiaTimepoint: BASELINE (DAY-1) AND AFTER 1 MONTH;To identify adverse drug reactions associated with erythropoiesis stimulating agents responsiveness in the anemia in chronic kidney disease patientTimepoint: BASELINE (DAY-1) AND AFTER 1 MONTH